Clincosm LogoSign in Get a demo

Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer

Sponsor
Protgen Ltd (Industry)
Overall Status
Unknown status
CT.gov ID
NCT02324101
Collaborator
(none)
1,100
Enrollment
1
Location
1
Arm
20
Duration (Months)
55
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients

Condition or Disease Intervention/Treatment Phase
  • Device: Hsp90
 N/A

Detailed Description

Detect plasma Hsp90α concentration of breast cancer patients, healthy volunteers, benign breast diseases patients, validate accuracy, specificity and sensitivity of Hsp90α kit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
1100 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
Clinical Trial of Quantitative Detection Kit for Hsp90α in Breast Cancer
Study Start Date :
Apr 1, 2013
Anticipated Primary Completion Date :
Dec 1, 2014
Anticipated Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: Breast cancer

Detect plasma Hsp90α concentration of breast cancer patients

Device: Hsp90
Detect plasma Hsp90α concentration
Other Names:
  • Biomarker

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Hsp90α Concentration(ng/ml) of plasma [4 months]

      Detect Hsp90α Concentration(ng/ml) of plasma and calculate the accuracy, specificity and sensitivity of Hsp90α kit

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • breast cancer patients, healthy volunteers, benign breast diseases patients
    Exclusion Criteria:
    • Patients who previously received radiotherapy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Tianjin cancer hospital Tianjin Tianjin China

    Sponsors and Collaborators

    • Protgen Ltd

    Investigators

    • Principal Investigator: Zhongsheng Tong, MD, Tianjin cance hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Protgen Ltd
    ClinicalTrials.gov Identifier:
    NCT02324101
    Other Study ID Numbers:
    • hsp90a2011-02
    First Posted:
    Dec 24, 2014
    Last Update Posted:
    Dec 24, 2014
    Last Verified:
    Apr 1, 2013
    Additional relevant MeSH terms:
    Breast Neoplasms

    Study Results

    No Results Posted as of Dec 24, 2014